Weekly Recap: PALISADE-2 met SUDS endpoint and itruvone/refisolone Phase 2a
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) said PALISADE-2 met its SUDS primary endpoint (p=0.015) and plans a U.S. Phase 3 LSAS program of ~350 participants, while repeat dosing improved anticipatory anxiety in public speaking and Phase 2a signals for itruvone (MDD) and refisolone (hot flashes) adv…